Ht-Logo-gigapixel-icon
Search
Close this search box.
Ht-Logo-gigapixel-icon
Search
Close this search box.
Wednesday, November 20, 2024
Canada’s Politics and Government News Source Since 1989
Latest Paper
Wednesday, November 20, 2024 | Latest Paper
Subscribe Now

TRENDING:

Lisa M. Olson

Lisa M. Olson is vice-president, immunology discovery at AbbVie and site head at the AbbVie Bioresearch Center.

Pharmaceutical innovation can help Canadians in pain, and the economy

  • Rheumatoid arthritis can debilitate bodies and crush spirits. It can also place a significant economic burden on individual patients, their families, and society. As
Opinion | BY LISA M. OLSON | November 20, 2019
While there has been tremendous progress in the treatment of rheumatoid arthritis over the past two decades, more than two-thirds of treated patients still do not achieve clinical remission or low disease activity treatment targets, writes Lisa M. Olson. Photograph courtesy of Adobe Stock/AbbVie Canada

Pharmaceutical innovation can help Canadians in pain, and the economy

Opinion | BY LISA M. OLSON | November 20, 2019
  • Rheumatoid arthritis can debilitate bodies and crush spirits. It can also place a significant economic burden on individual patients, their families, and society. As

Pharmaceutical innovation can help Canadians in pain, and the economy

Opinion | BY LISA M. OLSON | November 20, 2019
  • Rheumatoid arthritis can debilitate bodies and crush spirits. It can also place a significant economic burden on individual patients, their families, and society. As
While there has been tremendous progress in the treatment of rheumatoid arthritis over the past two decades, more than two-thirds of treated patients still do not achieve clinical remission or low disease activity treatment targets, writes Lisa M. Olson. Photograph courtesy of Adobe Stock/AbbVie Canada

Pharmaceutical innovation can help Canadians in pain, and the economy

  • Rheumatoid arthritis can debilitate bodies and crush spirits. It can also place a significant economic burden on individual patients, their families, and society. As
Opinion | BY LISA M. OLSON | November 20, 2019
While there has been tremendous progress in the treatment of rheumatoid arthritis over the past two decades, more than two-thirds of treated patients still do not achieve clinical remission or low disease activity treatment targets, writes Lisa M. Olson. Photograph courtesy of Adobe Stock/AbbVie Canada

Pharmaceutical innovation can help Canadians in pain, and the economy

Opinion | BY LISA M. OLSON | November 20, 2019
  • Rheumatoid arthritis can debilitate bodies and crush spirits. It can also place a significant economic burden on individual patients, their families, and society. As

Pharmaceutical innovation can help Canadians in pain, and the economy

Opinion | BY LISA M. OLSON | November 20, 2019
  • Rheumatoid arthritis can debilitate bodies and crush spirits. It can also place a significant economic burden on individual patients, their families, and society. As
While there has been tremendous progress in the treatment of rheumatoid arthritis over the past two decades, more than two-thirds of treated patients still do not achieve clinical remission or low disease activity treatment targets, writes Lisa M. Olson. Photograph courtesy of Adobe Stock/AbbVie Canada
More Stories

News

Get free news updates

Opinion

Submit a guest opinion article

resources

Advertise

get help

Subscribe
CloseMenu